Company Analysis - United Therapeutics

Company Analysis - United Therapeutics

  • July 2020 •
  • 41 pages •
  • Report ID: 5955613 •
  • Format: PDF
PharmaVitae explores United Therapeutics’ prescription pharmaceutical performance and outlook over 2019–29.

Snapshot
Overview – United Therapeutics’ prescription pharmaceutical business is heavily impacted by generic competition.
Key themes – [1] Generic competition is causing a severe impact on United Therapeutics’ pharmaceutical business, with Adcirca and Remodulin impacted in 2019 [2] Recent settlements with Watson and Actavis regarding generic versions of Tyvaso and Orenitram will keep generics at bay until 2026 and 2027 [3] Future growth depends on ralinepag, which United Therapeutics in-licensed from Arena for $1.2bn, with $800m upfront.

Model updates (29 April 2020)

No changes to forecasts.

Model updates (26 February 2020)

Tyvaso forecast adjusted higher due to results from Phase III INCREASE trial in patients with PH-ILD.

Model updates (7 November 2019)

Remodulin forecast adjusted higher due to larger number of patients treated and lower impact from generics in international markets
Unituxin forecast adjusted higher due to continued momentum in the US.

Model updates (12 July 2019)

Remodulin sales adjusted lower internationally due to generic entrants
Tyvaso sales adjusted higher due to delaying generic entry until 2026
Orenitram sales adjusted higher due to delaying generic entry until 2027
Removed esuberaprost from forecast after failed Phase III BEAT trial
Ralinepag forecast added.